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Abstract
Purpose Autoantibodies to intracellular ‘rods and rings’
structures (anti-rods/rings or anti-RR) are strongly associ-
ated with hepatitis C (HCV) patients treated with inter-
feron-a/ribavirin (IFN/RBV) and are linked with non-
responsiveness to IFN/RBV or relapse, especially in Italian
patients. This is the first study to determine whether there is
any correlation of anti-RR with non-responsiveness to IFN/
RBV treatment in patients also treated with telaprevir
(TPV), one of several new therapies for chronic HCV
recently implemented.
Methods From 2013 to 2014, 52 HCV-infected patients
were treated with IFN/RBV and TPV at five Italian clinics.
Patient sera were collected and analyzed by indirect
immunofluorescence for the presence of anti-RR
antibodies. Patients were classified as anti-RR positive or
anti-RR negative, and then various biological and clinical
variables were analyzed to compare the two groups,
including gender, age, HCV genotype, previous IFN/RBV
treatment, and IFN/RBV/TPV treatment outcome.
Results Of these 52 HCV patients treated with IFN/RBV/TPV,
10/32 (31%) who previously received IFN/RBV were anti-RR
positive, compared to 0 of 20 treatment-naı¨ve patients. Anti-
RR-positive patients relapsed more than anti-RR-negative
patients (3/10, 30% vs. 2/42, 5%; p\0.05). However, zero
anti-RR-positive patients were non-responsive, and frequencies
of sustained virological response were similar (anti-RR posi-
tive: 7/10, 70% vs. anti-RR negative: 33/42, 79%).
Conclusions Overall, the data suggest that anti-RR
seropositivity is not associated with resistance to TPV
treatment in this patient cohort, but monitoring anti-RR-
positive patients for relapse within the first 6 months after
treatment may be useful.
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Introduction
Chronic hepatitis C (HCV) infection is associated with the
production of autoantibodies, including organ-specific
autoantibodies directed against targets in the thyroid, adrenal
cortex, pancreatic islet cells, and gastric parietal cells, and
non-organ-specific autoantibodies such as antinuclear, anti-
smooth muscle, anti-mitochondrial, anti-liver/kidney
microsomal, and anti-neutrophil cytoplasmic antibodies
[1–8]. Recent studies have also demonstrated a link between
HCV and the production of autoantibodies targeting intra-
cellular filamentous structures termed ‘rods and rings’ (RRs)
[9–16]. In most studies, anti-rods/rings (anti-RR) seroposi-
tivity appears to be almost exclusive to HCV patients treated
with interferon-a and ribavirin combination therapy (IFN/
RBV) and is rarely seen in treatment-naı¨ve HCV patients or
other disease groups. However, anti-RR has been observed in
one hepatitis B patient [11], one systemic lupus erythe-
matosus patient [17], and healthy individuals with no pre-
vious IFN/RBV treatment [17]. In cultured cells, RRs are
composed of inosine 50-monophosphate dehydrogenase
(IMPDH), and/or cytidine 50-triphosphate synthase under
certain conditions [9, 18, 19]. RRs tend to assemble when de
novo purine biosynthesis is inhibited and guanine nucleotide
levels become depleted [20–25]. Many patients with anti-RR
react with IMPDH, which is inhibited by direct binding to
RBV and appears to be the major autoantigen in RRs
[9, 26, 27]. Although no mechanistic evidence suggesting
that anti-RR autoantibody contributes to resistance to IFN/
RBV therapy has yet been reported, previous studies showed
that anti-RR antibodies were more prevalent in patients who
did not respond to therapy or relapsed, when compared to
sustained responders [10, 15]. Additionally, non-responsive
or relapsing patients had higher anti-RR titers, suggesting
that anti-RR positivity may be indicative of poor treatment
outcomes [28]. In recent years, direct-acting antivirals
(DAAs), such as telaprevir (TPV), have been developed for
chronic HCV infection in an effort to reduce therapy duration
and increase drug tolerability, while also improving patient
outcomes. Currently, TPV is included with IFN/RBV as a
triple therapy. Here, we examine the relationship between
anti-RR and treatment outcomes in a cohort of Italian
patients treated with IFN/RBV and telaprevir.
Methods
Patient and treatment information
From 2013 to 2014, 52 HCV-infected patients were treated
with IFN/RBV and TPV at five Italian clinics located at the
(1) Ospedale San Antonio, Tolmezzo, (2) Ospedale Santa
Chiara, Trento, (3) Universita` degli Studi di Siena, (4)
Ospedale Regionale, Treviso, and (5) Universita` degli
Studi di Genova. Dosages depended on patient weight
(75 kg discriminating weight) and were typically admin-
istered as follows: 80–180 lg weekly pegylated interferon-
a, 600–1400 mg daily ribavirin, and 2250 mg daily TPV.
Patients were classified as: not responsive to therapy (HCV
RNA still detectable at week 24 of therapy), relapsed (HCV
RNA detectable after the end of treatment in patients with
previous virological response), or responsive to therapy
(HCV RNA not detectable in the 24 weeks after the
completion of therapy). The study conforms to the Insti-
tutional Review Board requirements in all institutions.
Informed consent Informed consent was obtained from
all individual participants included in the study. All
patients provided written informed consent to receive IFN/
RBV/TPV and permission for use of their medical records
for this study.
Antinuclear antibody indirect immunofluorescence
assay (ANA-IIF)
Anti-rods/rings in patient sera were detected by indirect
immunofluorescence, using NOVA Lite HEp-2 ANA sub-
strate (INOVA Diagnostics, San Diego, CA: 508100) as
previously described [10]. Staining patterns of test sera
were compared to staining of human prototype anti-RR
serum It2006 used in previous studies [9, 10]. It2006 and
all anti-RR-positive sera described in this study correctly
recognize the rods and rings ANA pattern, designated as
pattern AC-23 by the International Consensus on ANA
Patterns (ICAP) [29]. All sera were tested at a dilution of
1:80 in PBS as previously described [30]. For anti-RR-
positive patients who also had serial samples available,
anti-RR end point titers were determined using twofold
serial dilution of sera in PBS, with a starting dilution of
1:80 and ending dilution of 1:1280. Anti-RR positivity and
titers were independently validated by two trained indi-
viduals (S.J.C. and T.N.). End point titer was defined by
more than 50% of cells containing detectable RR staining.
Donkey anti-human IgG conjugated to DyLight 488
(Jackson ImmunoResearch, West Grove, PA) diluted 1:100
in PBS was used to detect autoantibody staining. Fluores-
cent images were captured with a Zeiss Axiovert 200 M
microscope fitted with a Zeiss AxioCam MRm camera
using a 409 (0.75 NA) objective (Carl Zeiss Microscopy,
Jena, Germany).
Statistical analysis
Biological and clinical variables analyzed for statistical
significance include: gender, age, HCV genotype, previous
treatment with IFN/RBV (prior to beginning of TPV
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regimen), and treatment outcome (see Table 1). Mann–
Whitney U test was used to compare different groups
containing continuous data, and Fisher’s exact test or the
Fisher–Freeman–Halton exact test was used for categorical
data. Differences were considered statistically significant if
p\ 0.05. Mann–Whitney U test and Fisher’s exact test
were performed using GraphPad Prism 5.0 (GraphPad
Software, La Jolla, CA). Fisher–Freeman–Halton test was
performed using StatXact 10 (Cytel, Cambridge, MA).
Results and discussion
The goal of this study was to probe for an association
between the presence of anti-RR autoantibody and treat-
ment outcome in a cohort of 52 Italian HCV patients
treated with the new DAA telaprevir. This is the first study
to examine anti-RR in patients treated with any of the
recently approved DAAs. It must be pointed out that, in
general, the availability of patients for studies of anti-RR
antibody is naturally limited by the low prevalence of this
autoantibody response. Although it has been reported that
20–40% of HCV patients treated with IFN/RBV produce
anti-RR autoantibodies, this response is very rarely
observed in treatment-naı¨ve HCV patients or other disease
groups [10, 11, 14–16, 31].
A total of 52 HCV-infected patients were treated with
IFN/RBV and TPV. Thirty-six patients (69%) were male
and 16 (31%) were female, with a mean age of
54 ± 9 years. Twelve patients (23%) had genotype 1a, 39
patients (75%) had genotype 1b, and one patient (2%) had
genotype 3b. Thirty-two patients (62%) had been previ-
ously treated with IFN/RBV prior to being put on TPV.
Patient demographics are included in Table 1. All 52
patients were assayed for the presence of anti-RR accord-
ing to standard antinuclear antibody indirect immunofluo-
rescence (ANA-IIF) protocols using HEp-2 cells as a
substrate. ANA-IIF analysis revealed that 10 out of 52
patients (19%) were positive for anti-RR at a dilution of
1:80. Figure 1 displays the images of the ‘rods and rings’
staining pattern from all ten anti-RR-positive patients
(patient codes C1TN, FV1S, TBN1S, VA1S, TG1TO,
SL1G, VG1G, MS1G, RC1G, and CB1G). Anti-RR-nega-
tive patients CD2T and E1TN are also shown for com-
parison. Twenty-one out of 52 patients had serial
collections of sera available (104 total sera for 52 patients),
representing multiple visits to the clinic over time periods
ranging from 2 weeks to 13 months. Anti-RR status did not
change over time in any of these 21 patients (i.e., anti-RR-
positive patients remained positive and negative patients
remained negative) and anti-RR titers did not significantly
change in positive patients. Accordingly, for purposes of
statistical analysis, patients were simply considered either
positive or negative, and serial collections were not taken
into consideration.
Patients were divided into two main groups, anti-RR-
positive (n = 10) and anti-RR-negative (n = 42), for
subsequent statistical analysis. These groups were
Table 1 Summary of anti-RR autoantibody reactivity in HCV patients treated with interferon-a/ribavirin and telaprevir
Parameters Total patients (n = 52) Anti-RR-positive patients (n = 10) Anti-RR-negative patients (n = 42) p value
Male 36 (69%) 7 (70%) 29 (69%) NS
Female 16 (31%) 3 (30%) 13 (31%) NS
Age (years) ± SD 54 ± 9 53 ± 14 54 ± 8 NS
Genotype 1a# 12 (23%) 3 (30%) 9 (21%) NS
Genotype 1b# 39 (75%) 7 (70%) 32 (76%) NS
Previous IFN/RBV 32 (62%) 10 (100%) 22 (52%) \0.01
Treatment outcome
SVR, no side effects 35 (67%) 6 (60%) 29 (69%) NS
SVR, but side effects 5 (10%) 1 (10%) 4 (10%) NS
SVR, combined 40 (77%) 7 (70%) 33 (79%) NS
Relapse 5 (10%) 3 (30%) 2 (5%) \0.05
No response 7 (13%) 0 (0%) 7 (17%) NS
Fisher–Freeman–Halton exact test
Anti-RR positive vs. anti-RR negative, with SVR separated NS
Anti-RR positive vs. anti-RR negative, with SVR combined \0.05
Values presented as n (%) unless otherwise indicated
Anti-RR anti-rods/rings autoantibody, IFN/RBV interferon-a/ribavirin therapy, NS not statistically significant (p[ 0.05), SD standard deviation,
SVR sustained virological response
# One patient without anti-RR was genotype 3b
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compared based on several demographic, clinical, and
serological parameters to determine any differences
between anti-RR-positive and anti-RR-negative patients
(Table 1). There was no significant difference observed
between the two groups when comparing gender, age, or
HCV genotype. Both patient groups were also categorized
into four different treatment outcome groups: (1) sustained
virological response (SVR) with no side effects, (2) initial
SVR but therapy was discontinued due to side effects, (3)
relapse within 6 months of treatment, and (4) no response
to treatment. SVR patients with or without side effects
were all determined to be SVR at the same time point (after
1 month, according to international guidelines). When the
Fisher–Freeman–Halton exact test was performed to com-
pare anti-RR-positive vs. anti-RR-negative patient groups
based on all four treatment outcome parameters, no sig-
nificant difference was observed. However, additional
Fisher–Freeman–Halton analysis with all SVR patients
combined (regardless of side effects) resulted in a statisti-
cally significant p value \0.05 (Table 1, bottom row).
Thus, our data indicate that anti-RR-positive and anti-RR-
negative patients in this cohort appear to differ with regard
to distribution of treatment outcomes. The most
notable difference is that anti-RR-positive patients were
more likely to relapse than anti-RR-negative patients
(p\ 0.05). Despite the increase in relapse, 0 of the 10 anti-
RR-positive patients were non-responsive to therapy,
compared to 7 of the 42 (17%) anti-RR-negative patients
(p = 0.32). Additionally, there was no significant differ-
ence in SVR rates between both groups. SVR rates were
compared with patients who experienced side effects and
those who did not separated as different outcomes (‘‘SVR,
but side effects’’ and ‘‘SVR, no side effects’’) or with all
SVR patients combined (‘‘SVR, combined’’), but both
Fig. 1 Anti-rods/rings seropositivity detected by the ANA-IIF assay.
Fifty-two Italian HCV patients were subjected to the antinuclear
antibody indirect immunofluorescence (ANA-IIF) assay. Anti-rods/
rings autoantibody was detected in 10 of 52 patients (19%), shown by
the ‘rods and rings’ ANA pattern in patient codes C1TN, FV1S,
TBN1S, VA1S, TG1TO, SL1G, VG1G, MS1G, RC1G, and CB1G.
Arrows point to examples of rods, which are most often observed in
cytoplasmic and perinuclear regions (see C1TN, RC1G, or CB1G for
examples of perinuclear rods). Arrowheads point to rings, which may
sometimes appear twisted into a ‘‘hairpin’’ shape, as in the bottom left
corner of the panel TG1TO. CD2T and E1TN are negative for anti-
rods/rings and are included for comparison. CD2T contains no
detectable autoantibody reactivity, while E1TN displays the nuclear
speckled ANA pattern. All panels shown are of sera tested at 1:80
dilution and detected by donkey anti-human IgG conjugated to
DyLight 488. All images were taken with a 409 objective
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analyses showed no significant difference between anti-
RR-positive and anti-RR-negative patients.
We also discovered that anti-RR can be detected years
after treatment with IFN/RBV. Two of the ten anti-RR-
positive patients had serum collected both prior to and after
IFN/RBV/TPV therapy was initiated. All samples from both
patients were positive for anti-RR, initially suggesting that
these patients may have been positive with no previous IFN/
RBV treatment. However, after careful examination of
medical records, it was determined that both patients had
received IFN/RBV more than a decade prior to treatment
with TPV. Patient TBN1S was diagnosed with liver cirrhosis
in 2000 and treated with IFN/RBV from 2000 to 2002, but
treatment was eventually discontinued due to side effects. In
2014, TBN1S began receiving IFN/RBV again with addition
of TPV, but relapsed within 6 months. Patient VA1S pre-
viously received IFN/RBV for 6 months in 2003. Eleven
years later, in 2014, the patient began receiving IFN/RBV
again with addition of TPV, but therapy was discontinued
due to side effects. Despite the lack of exposure to IFN/RBV
for more than 10 years, both patients remained positive for
anti-RR autoantibody, and VA1S even remained positive
down to 1:1280 dilution. We speculate that long-lived
plasma cells might be responsible for the long-term presence
of anti-RR antibody in these patients. Previous studies have
suggested that anti-RR titer increases throughout the dura-
tion of therapy, but declines upon cessation of treatment
[11, 12, 15, 31]. To our knowledge, this is the first report of
long-lived anti-RR autoantibody.
Previous studies established a strong association between
anti-RR and IFN/RBV therapy [10–12, 14, 15], such that we
previously described anti-RR as a drug-induced autoanti-
body [13]. Additionally, prolonged exposure to IFN/RBV
increases the likelihood of anti-RR autoantibody production
[11, 12, 15]. Our data support these findings, considering that
10 out of 32 (31%) patients previously treated with IFN/RBV
were anti-RR positive, compared to 0 out of 20 patients who
had not previously received IFN/RBV. In terms of treatment
outcome, previous reports have indicated a link between
anti-RR and non-responsiveness or relapse in American and
Italian HCV patient cohorts [10, 15, 28]. In the current study
with a new cohort of Italian patients, we again found that
anti-RR seropositivity was associated with increased fre-
quency of relapse. Interestingly, the frequency of non-re-
sponsiveness appeared to be decreased in anti-RR-positive
patients (0/10, 0%) compared to anti-RR-negative patients
(7/42, 17%), despite the opposite trend in relapse. When
patients with no previous IFN/RBV treatment are removed
from analysis, the trend remains similar, with non-respon-
siveness occurring in 0/10 (0%) of anti-RR-positive patients
compared to 6/16 (27%) of anti-RR-negative patients
(p = 0.14). Overall, 19% (10/52) of HCV patients in this
study were positive for anti-RR, which is similar to the rates
observed in previous studies [10, 11, 14–16]. Importantly,
the addition of TPV to the IFN/RBV regimen did not induce a
new anti-RR response in any patients; anti-RR-negative
patients previously treated with IFN/RBV did not become
positive after TPV was included in the regimen. Likewise,
anti-RR titers did not significantly change after addition of
TPV in anti-RR-positive patients with serial samples avail-
able. In all, our data suggest that inclusion of TPV in the IFN/
RBV regimen for the treatment of chronic HCV does not
alter the production of anti-RR autoantibody. However,
based on the statistically significant increase in relapse rate,
it may be useful to carefully monitor anti-RR-positive
patients during and for 6 months after IFN/RBV/TPV ther-
apy. While our study is limited by the number of available
patients, the data indicate that anti-RR seropositivity does
not affect the response to TPV treatment for chronic HCV.
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